2602.HK
Onewo Inc. on Tuesday announced a plan to repurchase up to HK$632 million ($81 million) worth of its shares in the open market.

The latest: Onewo Inc. (2602.HK) on Tuesday announced a plan to repurchase up to HK$632 million ($81 million) worth of its shares in the open market.

Looking up: Such share repurchases are meant to signal management’s optimism about the company’s prospects, as well as its belief that the shares are undervalued.

Take Note: The actual repurchase price will be determined by market conditions. The company does not guarantee that it will actually spend all the allocated money to buy back shares.

Digging Deeper: Onewo is a property management company spun off and separately listed by China Vanke (2202.HK; 000002.SZ), one of China’s leading developers. The company raised just HK$5.6 billion from its Hong Kong listing in September last year, far below its rumored target of HK$15.6 billion, as the country’s property market was already starting to show signs of stress after years of strong growth. Its shares have been sluggish in their first year of trading.

Market Reaction: Onewo’s shares closed up 4.1% at HK$22.7 by the midday break on Wednesday, 54% below its IPO price of HK$49.35 last year.

Translation by A. Au

Have a great investment idea but don’t know how to spread the word? We can help! Contact us for more details.

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…